BioResearch

Cell List

Integrated Solutions forPrimary Cells and Transfection

Making the Most of Your Primary
Cell Research

Clonetics™ and Poietics™ Primary Cells and Media

Lonza is the world’s leading provider of primary cells. With our trusted
brands of Clonetics™ and Poietics™ Primary Cells and Media, we offer
complete and ready-to-use systems for cell culture that guarantee
cell performance and more biologically relevant results from yourresearch. This brochure includes a complete listing of all Clonetics™
and Poietics™ Primary Cell Types available. To make your research evenmore biologically relevant, we now offer various primary cell types from
diseased tissue.
Over the past decade, Nucleofector™ Technology has become the provenmethod for transfection of hard-to-transfect cell lines and primarycells. The combination of cell-type specific electrical parameters,
Nucleofector™ Solution and protocol yields high transfection efficiency
paired with high cell viability and maintenance of cell functionality. With
our Nucleofector™ Instrument Platform you can now transfect from single
cuvettes up to 384-well plates, transfer protocol conditions between all
given Nucleocuvette™ Formats and transfect certain primary cells atlater developmental stages in adherence. Throughout this list you willfind numerous examples of transfection results for primary cells andcell lines, for further details please visit us at:

4D-Nucleofector™ Systemwww.lonza.com/celldatabase
Transfection performance data is based upon both data from Lonza R&D
and on customer data. If no transfection data are available, we havelisted the Nucleofector™ Kit recommended for optimization of this celltype. Transfection performance values are validated in combination
with Clonetics™ and Poietics™ Cells and Media only when marked withan asterisk (*).

Nucleofector™ 96-well Shuttle™ Device

Combining high quality primary cells, media and supplements with theleading transfection technology for primary cells significantly reduces
validation and optimization tasks at every step, as well as eliminating
dissection and cell isolation – meaning that your efforts can be focusedon getting the best possible assay data.
In this brochure, you will find a list of available Clonetics™ and Poietics™
Primary Cells and Media as well as related Nucleofector™ Kits. For acomplete list of available formats per cell, media and Nucleofector™ Kit,
please refer to our catalog or go to:www.lonza.com/research

Nucleofector™ 2b DevicePrimary Cells
Cell Name

Clonetics™ & Poietics™ Cell Culture Products

Nucleofector™ 2b/lls

Cell Cat. No. Recommended Media Cat
MediumNo.

Efficiency

Viability

4D-Nucleofector™ and 96-well Shuttle™
*

Cat. No.

Efficiency

Viability*

Solution

Cat.No.4DNucleofector™

Cat.No. 96-Well
Shuttle™

Adrenal Cells
Adrenocortical, bovine (BAC)

32–34%

VPI-1005

V4XP-9096

Chromaffin cells, cow

25–50%

VPI-1003

V4XP-9096

Bone/Cartilage Cells
Chondrocyte, human

CC-2550

CGM™

CC-3216

Osteoblasts, calvariae, rat

R-OST-583

OGM™

CC-321665%

60–70%*

VPF-1001

74%

84%

*

P3

V4XP-3032
V4XP-9096

Osteoblasts (NHOst ), human

CC-2538

OGM™

CC-3216

V4XP-9096

V4SP-3096

Dermal Cells
Keratinocyte, adult (NHEK–Ad), human

192627

KGM-Gold™

19576951%

40–60%*

VPD-1002

Keratinocyte, neonatal, pooled (NHEK–neo), 192906
human

KGM-Gold™

19576939–53%

50–60%*

VPD-1002

Keratinocyte, neonatal, single (NHEK-neo)
human

192907

KGM™ Gold

195769Keratinocyte, adult, diseased, Diabetes T2(D-HEK-Ad), human

CC-2926

KGM™ Gold

195769Melanocyte, neonatal (NHEM–neo), human

CC-2504

MGM™ 4CC-324970%

55–60%*

VPD-1003

Melanocyte, adult (NHEM–ad), human

CC-2586MGM™ 4CC-3249

Endothelial, aortic (BAEC), bovine

BW-6002

EGM™ MV

CC-312570–90%

Endothelial, aortic, human (HAEC)

CC-2535

EGM™ 2CC-3162

60%

95%

Endothelial, aortic, diseased Diabetes T1(D-HAEC), human

CC-2919

EGM™ 2CC-3162

Endothelial, aortic, diseased Diabetes T2(D-HAEC), human

CC-2920

EGM™ 2CC-3162
50–60%

70–90%

Endothelial, coronary art.(HCAEC), human

CC-2585

EGM™ 2MV

CC-3202

57%

42%

Endothelial, coronary artery, diseased
Diabetes T1 (D-HCAEC), human

CC-2921

EGM™ 2MV

CC-3202

Endothelial, coronary artery, diseased
Diabetes T2 (D-HCAEC), human

CC-2922

EGM™ 2MV

CC-3202

Endothelial, iliac art.(HIAEC), human

CC-2545

EGM™ 2MV

CC-3202
66–82%

99%

V4XP-9096
59–78%

57–79%*P3

V4XP-3032

V4XP-9096
V4XP-9096

Endothelial Cells

Endothelial, aortic, pig

Endothelial, lung, sheep
Endothelial, mammary, humanEndothelial, pulmonary artery (HPAEC),
human* indicates Lonza validated data

VPI-1001

P5

V4XP-5032

V4SP-5096

P5

V4XP-5032

V4SP-5096

VPI-1001

P5

V4XP-5032

V4SP-5096

VPB-1001

P5

V4XP-5032

V4SP-5096

VPI-1001

P5

V4XP-5032

V4SP-5096

VPI-1001

P5

V4XP-5032

V4SP-5096

P5

V4XP-5032

V4SP-5096

P5

V4XP-5032

V4SP-5096

VPI-1001*

VPI-1001
CC-2530

EGM™ 2CC-3162

VPI-100173%

50–90%

70%

Clonetics™ & Poietics™ Cell Culture Products

Nucleofector™ 2b/lls

4D-Nucleofector™ and 96-well Shuttle™

Cell Name

Cell Cat. No. Recommended Media Cat
MediumNo.

Efficiency

Viability*

Cat. No.

Efficiency

Viability*

Solution

Cat.No.4DNucleofector™

Cat.No. 96-Well
Shuttle™

Endothelial, pulmonary artery, diseased
Diabetes T1 (D-HPAEC), human

CC-2923

EGM™ 2CC-3162

Endothelial, pulmonary artery, diseased
Diabetes T2 (D-HPAEC), human

CC-2924

EGM™ 2CC-3162

Endothelial, umbilical vein (HUVEC), human

CC-2519

EGM™

CC-312490%

60–74%*

VPB-1002

62–90%

55–76%*P5

V4XP-5032

V4SP-5096

Endothelial, umbilical vein (HUVEC-XL)

191027

EGM™ 2CC-3162

Trabecular meshwork, human

80%

80%

VPI-1001

P5

V4XP-5032

V4SP-5096

Trabecular meshwork, pig

70%

60%

VPI-1001

P5

V4XP-5032

V4SP-5096

Microvascular Endothelial Cells
Endothelial, microvascular, bladder (HMVEC– CC-7016
Bd)

EGM™ 2MV

CC-3202

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, brain (bMVEC),
bovineAC-2509

EMVB

AC-3103

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, cardiac(HMVEC–C), human

CC-7030

EGM™ 2MV

CC-3202

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, derm. blood,
adult (HMVEC–dBlAd), human

CC-2811

EGM™ 2MV

CC-3202

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, derm. blood, neo(HMVEC–dBlneo), human

CC-2813

EGM™ 2MV

CC-3202

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, derm. lymphatic,
adult (HMVEC–dLyAd), human

CC-2810

EGM™ 2MV

CC-3202

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, derm. lymphatic,neo (HMVEC–dLyNeo), human

CC-2812

EGM™ 2MV

CC-3202

VPI-1001

P5

V4XP-5032

V4SP-5096

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, dermal, adult(HMVEC–d–Ad), human

CC-2543

EGM™ 2MV

CC-3202

64%

99%

VPI-1001

P5

Endothelial, microvascular, dermal, neo(HMVEC–d–Neo), human

CC-2516

EGM™ 2MV

CC-3202

61%

93%

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, dermal, diseased, CC-2929
Diabetes T1 (D-HMVEC), human

EGM™ 2MV

CC-3202

Endothelial, microvascular, dermal, diseased, CC-2930
Diabetes T2 (D-HMVEC), human

EGM™ 2MV

CC-3202

Endothelial, microvascular, lung (HMVEC–L), CC-2527
human

EGM™ 2MV

CC-3202

52%

52%

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, lung lymphatic(HMVEC–LLy), human

CC-2814

EGM™ 2MV

CC-3202

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, microvascular, myouterine(UtMVEC), human

CC-2564

EGM™ 2MV

CC-3202

VPI-1001

P5

V4XP-5032

V4SP-5096

Endothelial, derm.(HMVEC–d), human neo.

90%*

VPB-1003

79%

48%

V4SP-5096

Epithelial Cells
Cytotrophoblast, human

60–70%

60%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, alveolar, rat

19–24%

30–60%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, airway, pig

80%

75%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096* indicates Lonza validated dataCell Name

Clonetics™ & Poietics™ Cell Culture Products

Nucleofector™ 2b/lls

4D-Nucleofector™ and 96-well Shuttle™

Cell Cat. No. Recommended Media Cat
MediumNo.

Efficiency

Viability*

Cat. No.

Efficiency

Viability*

Solution

Cat.No.4DNucleofector™

Cat.No. 96-Well
Shuttle™

50–65%

50%*

VPK-1001

54%

53%

*

P3

V4XP-3032

V4SP-3096

Epithelial, bronchial (NHBE), with RA, human CC-2540S

BEGM™

CC-3170

Epithelial, bronchial (NHBE), without RA,
human

CC-2541

BEGM™

CC-3170

Epithelial, bronchial, diseased Asthma(DHBE-As), human194911BEGM™

CC-3170

VPK-1001

72%

75%

*

P3

V4XP-3032

V4SP-3096

Epithelial, bronchial, diseased COPD (DHBECOPD), human195275

BEGM™

CC-3170

VPK-1001

63%

80%

*

P3

V4XP-3032

V4SP-3096

Epithelial, bronchial, diseased Cystic Fibrosis 196979(DHBE-CF), human

BEGM™

CC-3170
VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, bronchial, monkey
Epithelial, cervical, human

70–80%
CC-2548

KGM™ Gold
Bullet Kit

195769Epithelial, cornea, human

40–50%

70%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, ES-derived, human

41%

92%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, kidney, human

40%

65%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, lung type II, human

20–40%

50%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

73%

66–98%P3

V4XP-3032

30–50%

70%

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

43%

64%

Epithelial, mammary (HMEC), human

CC-2551

MEGM™

CC-3150Epithelial, mammary, mouse*

VPK-1002

51%

66%

*

VPI-1005

Epithelial, prostate (PrEC), human

CC-2555

PrEGM™

CC-3166

P1

V4XP-1032

Epithelial, renal cortical (HRCE), human

CC-2554

REGM™

CC-3190

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, renal (HRE), human

CC-2556

REGM™

CC-3190

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, renal proximal tubule cells(RPTEC), human

CC-2553

REGM™

CC-3190

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, renal proximal tubule, diseased
Diabetes T2, (D-RPTEC), human

CC-2925

REGM™

CC-3190

Epithelial, retinal pigment (H-RPE), human194987

RtEGM™

19540930–40%

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Epithelial, small airway, human (SAEC)

CC-2547

SAGM™

CC-3118

47%

96%

VPI-1005

P1

V4XP-1032

Epithelial, small airway, diseased Asthma(D-SAEC), human

CC-2932

BEGM™

CC-3170

Epithelial, small airway, diseased Cystic
Fibrosis (D-SAEC), human

CC-2933

BEGM™

CC-3170

Epithelial, small airway, diseased COPD
(D-SAEC), human

CC-2934

BEGM™

CC-3170

Podocyte, mouse

70%

80%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Turbinate cell, cow

90%

70%

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

43%

60–80%

76%

50%

70%

*

90%

VPK-1003

67%

48%

*

V4SP-3096

VPI-1005
64%

60–100%V4SP-1096

V4SP-1096

Fibroblasts
Embryonic fibroblast (MEF), mouse

M-FB-481

DMEM

12-604F

Embryonic fibroblast, chicken
Fibroblast, aortic adventitial, human (AoAF)
Fibroblast, cow* indicates Lonza validated data

CC-7014

SCGM™

CC-3205*

VPD-1006

P4

V4XP-4032

VPI-1002

67–89%

75–90%*

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

V4SP-4096

60–70%

70–75%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

85%

71–72%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Clonetics™ & Poietics™ Cell Culture Products

Nucleofector™ 2b/lls

Cell Name

Cell Cat. No. Recommended Media Cat
MediumNo.

Efficiency

Viability*

Cat. No.

Efficiency

Viability*

Solution

Cat.No.4DNucleofector™

Cat.No. 96-Well
Shuttle™

Fibroblast, cardiac, atricular (NHCF-A),
human

CC-2903

FGM™ 3CC-4526

Fibroblast, cardiac, ventricular (NHCF-V),
human

CC-2904

FGM™ 3CC-4526

Fibroblast, dermal (NHDF), human – adultCC-2511

FGM™ 2CC-3132

42–69%

74–77%*

VPD-1001

92–96%

92–100%*P2

V4XP-2032

V4SP-2096

Fibroblast, dermal (NHDF), human – neo

CC-2509

FGM™ 2CC-313290%

85–90%*

VPD-1001

86–98%

86–91%*P2

V4XP-2032

V4SP-2096

Fibroblast, dermal, macaque

80%

81%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Fibroblast, ES–derived, human53%

70–73%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Fibroblast, foreskin, human

80–85%

79–82%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Fibroblast, human, GM06940

4D-Nucleofector™ and 96-well Shuttle™

59%

Fibroblast, lung (NHLF), human

CC-2512

FGM™ 2CC-3132

33–54%

68–73%

Fibroblast, lung, diseased Asthma (D-HLFAs), human194912

FGM™ 2CC-3132

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Fibroblast, lung, diseased COPD (D-HLFCOPD), human195277

FGM™ 2CC-3132

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Fibroblast, lung, diseased Cystic Fibrosis(D-HLF-CF), human194983

FGM™ 2CC-3132

Fibroblast, lung, mouse

20–30%

50%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Fibroblast, lung, rat

40–45%

50–88%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Fibroblasts, periodontal ligament (HPdLF),
human

CC-7049

SCGM™

CC-3205

Fibroblast, tunica albuginea, human

50%

50–90%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Synoviocyte, human

75%

90%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Myofibroblast, human hepatic

41–57%

VPI-1002

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

51–52%

VPI-1004

P2/P3

V4XP-2032/V4XP-3032 V4SP-2096/V4SP-3096

Myofibroblast, human intestinal

CC-2902

SmGM™

CC-3182

Myofibroblast, rat hepatic

Hematopoietic Cells
B cell, peripheral blood, CD19+, human36%

84–92%*

VPA-1001

28%

70%

*

P3

V4XP-3032

V4SP-3096

B-cell, mouse, stimulated

59%

27–47%*

VPA-1010

55–56%

41–87%*P4

V4XP-4032

V4SP-4096

V4XP-9096

V4SP-9096

93–99%

12–75%*

VPA-1004

V4XP-9096

V4SP-9096

Dendritic cell, mouse, immat. – BALB/c

58%

62%

*

VPA-1011

43%

37–49%*P4

V4XP-4032

V4SP-4096

Dendritic cell, mouse, immat. – C57BL/6

54%

52%

*

VPA-1011

34%

41–58%*P4

V4XP-4032

V4SP-4096

Dendritic cell, mouse, mature – BALB/c

49%

78%

*

VPA-1011

32%

85%

*

P3

V4XP-3032

V4SP-3096

Dendritic cell, mouse, mature – C57BL/6

37%

63%

*

VPA-1011

29%

88%

*

P3

V4XP-3032

V4SP-3096

V4XP-9096

V4SP-9096

42%

60%

*

P3

V4XP-3032

V4SP-3096
V4SP-9096

Bone marrow unprocessed, human

1M-105

Dendritic cell, human

CC-2701

LGM™ 3CC-3211

Dendritic cell, plasmacytoid, human

70–80%

VPA-1004

Macrophage, human

55–59%

87–88%*

VPA-1008

Macrophage, mouse – BALB/c

34–45%

84–92%*

VPA-1009

V4XP-9096

Macrophage, mouse – C57BL/6

24–47%

80–88%*

VPA-1009

V4XP-9096

V4SP-9096

60%

62–81%*

VPA-1007

V4XP-3032

V4SP-3096

Monocyte CD14+, human* indicates Lonza validated data

2W-400A

LGM™ 3CC-3211

64%

77%

*

P3

Clonetics™ & Poietics™ Cell Culture Products

Nucleofector™ 2b/lls

Cell Name

Cell Cat. No. Recommended Media Cat
MediumNo.

Efficiency

Mononuclear, bone marrow, baboon
Mononuclear, bone marrow, canine
Mononuclear, bone marrow, human

2M-125A

Mononuclear, bone marrow, murine

2S-101C

Mononuclear, peripheral blood, human
Natural killer (NK), human

Cat.No.4DNucleofector™

Cat.No. 96-Well
Shuttle™

2S-101A

V4XP-9096

V4SP-9096

2S-101B

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

HPGM™

PT-3926

CC-2702

LGM™ 3CC-32112W-501

LGM™ 3CC-3211Viability

4D-Nucleofector™ and 96-well Shuttle™
*

Cat. No.

Efficiency

Viability*

Solution54%

50–60%*

VPA-10058

41–47%

83–90%*

VPA-1002

70%

59%

*

P3

V4XP-3032

V4SP-3096

70–75%

85%*

VPA-1002

43–98%

51–92%*P3

V4XP-3032

V4SP-3096

T cell, mouse – BALB/c

44%

18–55%*

VPA-1006

45%

32%

*

P3

V4XP-3032

V4SP-3096

T cell, mouse – C57BL/6

20–28%

17–45%*

VPA-1006

43%

23%

*

P3

V4XP-3032

V4SP-3096

T cell, rabbit, stimulated

44%

47%

V4XP-9096

V4SP-9096

V4XP-3032

V4SP-3096

54%

80%

*

V4XP-9096

V4SP-9096

T cell, human stim.
T cell, peripheral blood, human unstim.

2W-200

LGM™ 3CC-3211

VPA-1002

Hepatocytes
Hepatocyte, human

CC-2591

HCM™

CC-3198

Hepatocyte, mouse54%

59–69%*P3

VPL-1002

Neural Cells
Astrocyte (NHA), human

CC-2565

AGM™

CC-3186

83%

P3

V4XP-3032

V4SP-3096

Astrocyte, mixed Brain, C57 mouse

M-AsM-330

AGM™

CC-318660%

60–70%*

VPG-1006

P3

V4XP-3032

V4SP-3096

Astrocyte, mixed Brain, CD1 mouse

M-AsM-430

AGM™

CC-318660%

60–70%*

VPG-1006

P3

V4XP-3032

V4SP-3096

Astrocytes, cortex, rat

R-CxAs-520

AGM™

CC-3186

VPG-1007

P3

V4XP-3032

V4SP-3096

Astrocytes, Cx–Hi–Cp Mix, rat

R-AsM-530

AGM™

CC-3186

VPG-1007

P3

V4XP-3032

V4SP-3096

Astrocytes, hippocampus, rat

R-HiAs-521

AGM™

CC-3186

VPG-1007

P3

V4XP-3032

V4SP-3096

Astrocytes, striatum,rat

R-CpAs-522 AGM™

CC-3186*

VPG-1007

P3

V4XP-3032

V4SP-3096*

VPG-1002

P3

V4XP-3032

V4SP-3096

VPG-1001

P3

V4XP-3032

V4SP-3096

P3

V4XP-3032

V4XP-3096

P3

V4XP-3032

V4SP-3096

V4XP-9096

V4SP-9096

Dorsal root gang. (DRG), chicken

67%

VPI-1003

70–80%

30%

Dorsal root gang. (DRG), mouse

40–60%

Dorsal root gang. (DRG), rat, embryonic

R-eDRG-515 PNGM™

CC-4461

Dorsal root gang. (DRG), rat, neo

R-Drg-505

PNGM™

CC-4461

Microglial, rat

R-G-535

PNGM™

CC-4461

Neurons, cerebellar granule (CGC), mouse41%

VPG-1003

30–51%

80%

VPG-1001

P3

V4XP-3032

V4SP-3096

50–70%

VPG-1003

P3

V4XP-3032

V4SP-3096

Neurons, cerebellar granule (CGC), rat

R-CB-503

PNGM™-A

CC-451250–60%

Neurons, cortical, C57 mouse

M-Cx-300

PNGM™

CC-446192%

Neurons, cortical, CD1 mouse

M-Cx-400

PNGM™

CC-446192%

Neuron, cortical, rat

R-Cx-500

PNGM™

CC-4461

54–67%

Neuron, hippocampal, chicken

*

85%

60%

43%

VPG-1001

20–50%

75–95%*P3

V4XP-3032

V4SP-3096
V4SP-3096

VPG-1001

20–50%

75–95%*P3

V4XP-3032*

VPG-1003

30–60%

60–95%*P3

V4XP-3032

V4SP-3096*

VPG-1002

P3

V4XP-3032

V4SP-3096*

VPG-1001

P3

V4XP-3032

V4SP-3096*

VPG-1003

P3

V4XP-3032

V4SP-3096

Neurons, hippocampal, mouse

M-Hi-401

PNGM™

CC-4461

58%

Neuron, hippocampal, rat

R-Hi-501

PNGM™

CC-4461

58–67%

Neurons, striatal, C57 mouse

M-Cp-302

PNGM™

CC-4461

75–85%

VPG-1001

P3

V4XP-3032

V4SP-3096

Neurons, striatal CD1 mouse

M-Cp-402

PNGM™

CC-4461

75–85%

VPG-1001

P3

V4XP-3032

V4SP-3096* indicates Lonza validated data

47–60%

30–60%

61–70%*

Clonetics™ & Poietics™ Cell Culture Products

Nucleofector™ 2b/lls

Cell Name

Cell Cat. No. Recommended Media Cat
MediumNo.

Efficiency

Neuron, striatal, rat

R-Cp-502

20–30%PNGM™

CC-4461

Viability

4D-Nucleofector™ and 96-well Shuttle™
*

Cat. No.

Viability*

VPG-1003

Olfactory neuron, rat

VPI-1003

Oligodendrocyte, rat

Efficiency*

50–60%

VPG-1009

Solution

Cat.No.4DNucleofector™

Cat.No. 96-Well
Shuttle™

P3

V4XP-3032

V4SP-3096

P3

V4XP-3032

V4SP-3096

P3

V4XP-3032

V4SP-3096

44%

60%

AML

20–70%

45–87%

contact SST

contact SST

AML–DC23%

61%

contact SST

contact SST

B–CLL

30–60%

75–90%

contact SST

contact SST

CML

42%

80%

contact SST

Neuroblastoma

20–90%

Pancreatic Islets
Pancreatic Islets, Fresh, Human
5,000/10,000/20,000/100,000 cells

201981/
83/84/85

Primary Cancer Cells

contact SST

contact SST

80%

VPC-1001

80%

contact SST

Smooth Muscle Cells
SMC, aortic (AoSMC), human

CC-2571

SmGM™ 2CC-3182

SMC, aortic, diseased Diabetes T1(D-AoSMC), human

CC-2914

SmGM™ 2CC-318275%

69–96%

SMC, aortic, diseased Diabetes T2(D-AoSMC), human

CC-2916

SmGM™ 2CC-3182

SMC, aortic (AoSMC), mouse

30–35%

99%

SMC, aortic (AoSMC), pig

80–90%

*

80%

*

P1

V4XP-1032

V4SP-1096

VPI-1004

P1

V4XP-1032

V4SP-1096

VPI-1004

P1

V4XP-1032

V4SP-1096

SMC, aortic (AoSMC), rat

R-ASM-580

DMEM/F12

BE04-687Q

37–75%

60–90%

VPI-1004

P1

V4XP-1032

V4SP-1096

SMC, bladder, human

CC-2533

SmGM™ 2CC-3182

80%

90%

VPI-1004

P1

V4XP-1032

V4SP-1096

SMC, bronchial (BSMC), human

CC-2576

SmGM™ 2CC-3182

59–63%

52–77%

VPI-1004

P1

V4XP-1032

V4SP-1096

SMC, bronchial, diseased Asthma (D-BSMCAS), human194850

SmGM™ 2CC-3182

VPI-1004

P1

V4XP-1032

V4SP-1096

SMC, bronchial, diseased COPD (D-BSMCCOPD), human195274

SmGM™ 2CC-3182

VPI-1004

P1

V4XP-1032

V4SP-1096

SMC, bronchial, diseased Cystic Fibrosis(D-BSMC-CF), human196980

SmGM™ 2CC-3182
P1

V4XP-1032

V4SP-1096

P1

V4XP-1032

V4SP-1096

P1

V4XP-1032

V4SP-1096

P1

V4XP-1032

V4SP-1096

SMC, cervix, human
SMC, coronary artery, human (CASMC)

CC-2583

SmGM™ 2CC-3182

SMC, coronary artery, diseased Diabetes T1(D-CASMC), human

CC-2917

SmGM™ 2CC-3182

SMC, coronary artery, diseased Diabetes T2(D-CASMC), human

CC-2918

SmGM™ 2CC-3182

SMC, pulmonary artery (PASMC), human

CC-2581

SmGM™ 2CC-3182

SMC, pulmonary artery, diseased Diabetes
T1 (D-PASMC), human

CC-2915

SmGM™ 2CC-3182

SMC, coronary, rat* indicates Lonza validated data

46–82%

81–90%

VPI-1004

65–95%

75–95%

VPI-1004

80–90%

40–80%

VPI-1004

60–85%

80%

VPI-1004

81%

100%

65–85%

55–65%

Clonetics™ & Poietics™ Cell Culture Products

Nucleofector™ 2b/lls

Cell Name

Cell Cat. No. Recommended Media Cat
MediumNo.

Efficiency

SMC, pulmonary artery, diseased Diabetes
T2 (D-PASMC), human

CC-2913

SmGM™ 2CC-3182

SMC, prostate (PrSMC), human

CC-2587

SmGM™ 2CC-3182

SMC, umbilical art. (UASMC), human

CC-2579

SmGM™ 2CC-3182

CC-2562

SmGM™ 2CC-3182

SMC, ureter, human
SMC, uterus, humanViability

4D-Nucleofector™ and 96-well Shuttle™
*

Cat. No.

Efficiency

Viability*

Solution

Cat.No.4DNucleofector™

Cat.No. 96-Well
Shuttle™

VPI-1004

P1

V4XP-1032

V4SP-1096

VPI-1004

P1

V4XP-1032

V4SP-1096

95%

90%

VPI-1004

P1

V4XP-1032

V4SP-1096

50–70%

78–83%

VPI-1004

P1

V4XP-1032

V4SP-1096

VPI-1004

P1

V4XP-1032

V4SP-1096

SMC, vascular, human
SMC, vascular, monkey

32%

70%

VPI-1004

P1

V4XP-1032

V4SP-1096

SMC, vascular, rat

69–76%

96–97%

VPI-1004

P1

V4XP-1032

V4SP-1096

Smooth muscle (SMC), rat

50–80%

90–95%

VPI-1004

P1

V4XP-1032

V4SP-1096

V4XP-9096

V4SP-9096

P3

V4XP-3032

V4SP-3096

P3

V4XP-3032

V4SP-3096

V4XP-9096

V4SP-9096

Stem Cells
Adipose stem cell, human67%

CD34 cell, cord blood, human

2C-101

HPGM™

PT-3926

CD34+ cell, bone marrow, human

2M-101

HPGM™

PT-3926

CD133+ cells, cord blood, human

2C-102

HPGM™

PT-3926

Dental pulp stem cells (DPSC), Human

PT-7601

DPSC

PT-7604+

Embryonic stem (ES) cell, human
Embryonic stem (ES) cell, mouse
Endothelial Colony Forming Cells (ECFCs)

189423

Erythroid progenitors, cord blood, human

2C-250

EGM™ 2 &Supplement

VPA-1003
82%

70%

*

Mesenchymal stem (MSC), human

PT-2501

MSCGM™

Mesenchymal stem (MSC), rat

PT-3001

PT-2505

RMSC Poietics™ 192853

Neural precursor, cow
NPMM

62%

*

50–96%*

VPH-5002

64%

98%

*

P3

V4XP-3032

V4SP-3096

87–90%

90–99%*

VPH-1001

50–90%

68–81%*P3

V4XP-3032

V4SP-3096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-1032

V4SP-1096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-4032

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-9096

V4SP-9096

V4XP-1032

V4SP-1096

V4XP-9096

V4SP-9096

VPA-1004

55–88%

50–86%

62–65%

73–75%*

VPE-1001

69–78%

65–71%*P1

VPI-1003

CC-3209

Neural stem cell (NSC), human90%

Neural stem cell (NSC), mouse82%*

VPG-1004

42–46%*

VPG-1005

Neural stem cell (NSC), rat
Osteoclasts, precursor, human

2T-110OPGM

PT-8001

Preadipocytes, subcutaneous, human

PT-5001

PGM™ 2PT-8002

Preadipocytes, subcutaneous, humanDiabetes Type I

PT-5021

PGM™ 2PT-8002

Preadipocytes, subcutaneous, humanDiabetes Type Il

PT-5022

PGM™ 2PT-8002

Preadipocytes, visceral , human

PT-5005

PGM™ 2PT-8002

Preadipocytes, visceral, human Diabetes
Type I

PT-5023

PGM™ 2PT-8002

Preadipocytes, visceral, human Diabetes
Type Il

PT-5024

PGM™ 2PT-8002* indicates Lonza validated data83%

20–78%

70%

PT-2599

VPA-1003

CC-3162/00190284

Langerhans cells, human

Neural progenitor (NHNP), human

VPE-1001

30–40%

30–40%

VPG-1004

50–80%

50–80%

VPI-1002

VPI-100260%

37–92%

80%

34–92%

P4*

P1

28–70%

28–75%*P1

V4XP-1032

V4SP-1096

37–92%

34–92%*P1

V4XP-1032

V4SP-1096

V4XP-9096

V4SP-9096

V4XP-1032

V4SP-1096

28–70%

28–75%*

P1

Clonetics™ & Poietics™ Cell Culture Products

Nucleofector™ 2b/lls

Cell Cat. No. Recommended Media Cat
MediumNo.

Efficiency

Viability*

Cat. No.

Efficiency

Viability

CorAT™ GFP Cardiomyocytes, mouse ESC
derived50–61%

80%*

VCA-1003

61%

86%

SG

CorAT™ Cardiomyocytes, mouse ESC derived

50–61%

80%*

VCA-1003

61%

86%

Cell Name

4D-Nucleofector™ and 96-well Shuttle™
*

Solution

Cat.No.4DNucleofector™

Cat.No. 96-Well
Shuttle™

V4XP-9096

V4SP-9096

V4XC-3032

V4SC-3096

SG

V4XC-3032

V4SC-3096

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

Stem Cell Derived Cells
Adipose–Derived Stem Cells (ADSC)

PT-5006

ADSC-GM

PT-4505

Retinal Cells
Retinal Cells, Rat

R-Ret-508

PNGM™

CC-4461Retinal Pigmented Epithelial Cells, human194987

RtEGM™

19540930–40%

R-CM-561

RCGM

CC-451575–80%

VPI-1005

Other Cells
Cardiomyocyte, rat
Cervical stromal cell, human

50–60%

30–40%
83%

81%*

V4XP-9096

V4SP-9096

VPI-1002

V4XP-9096

V4SP-9096

VPI-1004

V4XP-9096

V4SP-9096

Mesangial cell(NHMC), human

CC-2559

MsGM™

CC-3146

Prostate stromal cell (PrSC), human

CC-2508

SCGM™

CC-3205

V4XP-9096

V4SP-9096

Sertoli cell (HseC), human

MMHSE-2305

SeGM™

191053

V4XP-9096

V4SP-9096

Skeletal muscle cell(SkMC), human

CC-2561

SkGM™

CC-3160

V4XP-4032

V4SP-4096

Skeletal muscle myoblasts (HSMM), humanDiabetic Type I

CC-2900

SkGM™ 2CC-3245

V4XP-9096

V4SP-9096

Skeletal muscle myoblasts (HSMM), humanDiabetic Type Il

CC-2901

SkGM™ 2CC-3245

V4XP-9096

V4SP-9096

Skeletal muscle myoblasts (HSMM ), human

CC-2580

SkGM™ 2CC-3245

P5

V4XP-5032

V4SP-5096

VPD-1001

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

VPI-1005

P3/P1

V4XP-3032/V4XP-1032 V4SP-3096/V4SP-1096

55%

72–78%

Trophoblast, human95%

Trophoblast, mouse

10–20%

75%

80%

61%

P4

*

Parasites
B. boviscontact SST

contact SST

Leishmania t.

7%contact SST

contact SST

P. berghei

0.10–1%

contact SST

contact SST

P. marinus

38%

10%

contact SST

contact SST

40–60%

contact SST

contact SST

60–71%

contact SST

contact SST

P. yoelii
T. brucei* indicates Lonza validated data

10.80%

Cell Lines (Transfection Data Only)
Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

Viability

1205 Lu

Skin/Hair Epith.

90%

1321N1Glial Cells

53–80%

44–72%

143B

Bone

70%

22Rv1

Prostate Epith.

23132/87
293

4D-Nucleofector™ and 96-well Shuttle™
*

Cat.No.

Efficiency

Viability*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

50–60%

70–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

GI Tract Epith.

20%

89–93%

SE/SF/SGV4XC-9064

V4SC-9096

Kidney Epith.

84%

SF

V4XC-2032

V4SC-2096

293 [suspension]

Kidney Epith.

71%

80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

293-F FreeStyle™ (Life Technologies)

Kidney Epith.

96%

79%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

293T

Kidney Epith.

90%

90%

VCA-1003

SF

V4XC-2032

V4SC-2096

2A8

B cell42–50%

63–72%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

2PK3

B cell85%

90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

300.19B cell

97–98%

62–84%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

32D

Leukocyte (unspec.)

79%

61%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

3A9

T Cell30%

50–60%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

3T3-L1 ad

Fibroblast

25%

90%

*

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

3T3-L1 pre-ad

Fibroblast

73%

59%

*

VCA-1003

SE

V4XC-1032

V4SC-1096

3T3-Swiss albino

Fibroblast

70–80%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

4T1

Mammary Epith.

31–86%

51–78%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

5838 Ewing‘s

Bone

61–77%

88–92%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

661W

Eye Epith.

50–70%

60–70%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

697

B cell

15–58%

29–84%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

Jul-17

Dendritic cell (DC)

63%

62%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

720

T Cell81–92%

64–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

721.174

B cell20–26%

90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

721.22

B cell85%

75%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

721.221

B cell50–51%

53–71%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

786-0

Kidney Epith.

75%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

A-10

Smooth muscle cell

64%

74%

*

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

A-375

Skin/Hair Epith.

72%

97%

*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

A-431

Uterine/Vaginal Epith.

45%

83%

*

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

A-498

GI Tract Epith.

60%

70%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

0–9

VCA-1002**

VCA-1003

83–93%

73–93%*

40-95%

97%

66-79%*A* indicates Lonza validated dataNucleofector™ 2b/ lls

4D-Nucleofector™ and 96-well Shuttle™

Cell Name (short)

Cell Type

Efficiency

Viability*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

A-673

Myoblast

85–90%

90–99%

A172

Glial Cells

30%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

A2.A2

T Cell48%

45%

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

A20

B cell37–74%

81–95%*

VCA-1003

A2058

Skin/Hair Epith.

81%

94%

*

VCA-1004

SF

V4XC-2032

V4SC-2096

SE/SF/SGV4XC-9064

A2780

Ovary Epith.

80%

V4SC-9096

VCA-1005

SE/SF/SGV4XC-9064

A3.01

T Cell81%

83–93%

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

A549

Respiratory Tract Epith.

72%

81%

*

VCA-1002

V4SC-9096

SF

V4XC-2032

A7r5

Smooth muscle cell

49%

81%

*

V4SC-2096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

AGN2a

Neuroblast

60–99%AGS

GI Tract Epith.

73%

62%

*

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

ARH 77

B cell

27–51%

47–89%

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

ARPE-19

Eye Epith.

83%

92%

V4SC-9096

SE

V4XC-1032

ASZ001

Skin/Hair Epith.

50%

V4SC-1096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

AT-1

Leukocyte (unspec.)

66%

ATDC5

Cartilage

70–80%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

AtT20

Pituitary Gland Epith.

30–80%

V4SC-9096

50–55%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

B-cell lymphoma cell line

B cellb-END

Brain Endo.

65%

62%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

20–25%

70%

VCA-1003

SE/SF/SGV4XC-9064

B157

V4SC-9096

B cell50–60%

50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

B16-F0Skin/Hair Epith.

84%

91%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

B16-F1

Skin/Hair Epith.

80%

100%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

B16-F10

Skin/Hair Epith.

91%

96%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

B35

Neuroblast

28–36%

83–93%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

B65

Neuroblast

75%

95%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

BA/F3 (DSMZ)

B cell

88%

79%

SG

V4XC-3032

V4SC-3096

Balb/c 3T3

Fibroblast

83–88%

94–96%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

BC-1

Leukocyte (unspec.)47%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

BCBL1

B cell

57–84%

35–57%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

BCL1 clone 5B1b

B cell37%

75%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

BCL1.3B3

B cell26–33%

45–50%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

BE2-M17

Neuroblast

35–40%

100%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

BEAS-2B

Respiratory Tract Epith.

80%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

BeWo

Embryonic/
Extraembryonic Epith.

90%

85%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

Beta TC-6

Pancreas

BHK-21Kidney Epith.

85%

78%

*

36–46%

Cat.No.

VCA-1003

Efficiency

Viability

*

80%

81%

62%

*

87%

B

* indicates Lonza validated data

*
*

*

*

VCA-1003

VCA-1005

80%

60-70%

*

65%

66%

*

SF

V4XC-2032

V4SC-2096

86-96%

75-100%*SE

V4XC-1032

V4SC-1096

Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

Viability

BHP2-7Thyroid Epith.

77%

99%

BJ

Fibroblast

52%

76%

BJ1-hTERT

Fibroblast

50%

BJAB

B cellBJMC3879

Mammary Epith.

BL2

4D-Nucleofector™ and 96-well Shuttle™
*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

50%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

30–78%

58–93%

VCA-1002

SF

V4XC-2032

V4SC-2096

40–70%

95%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Leukocyte (unspec.)

48–96%

60–94%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

BL3

Leukocyte (unspec.)

64–82%

73–90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

BLCL

B cell67–80%

54–80%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

BPH1

Prostate Epith.

60–65%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

BRIN-BD11

Pancreas

40–50%

90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

BT-20

Mammary Epith.

40–50%

90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

BT549

Mammary Epith.

60%

SE

V4XC-1032

V4SC-1096

BV173

Leukocyte (unspec.)

19–36%

30–80%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

BV2

Glial Cells

56–70%

75–95%

VCA-1002

SF

V4XC-2032

V4SC-2096

BW5147.3

T Cell31%

48–54%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

BxPC-3

Pancreas Epith.

28%

62%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

C10/MJ2

T Cell35–49%

54–78%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

C17.2

Neuroblast

20%

50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

C28A2

Cartilage

90%

60%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

C2C12

Myoblast

82%

93%

SE

V4XC-1032

V4SC-1096

C2F3

Myoblast

85%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

C3H10T1/2

Mesenchyme

85–90%

80–90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

C57MG

Mammary Epith.

40–70%

90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

C6

Glial Cells

94%

75–80%SF

V4XC-2032

V4SC-2096

C8161

Skin/Hair Epith.

90%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

CA46

B cell78%

91%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

Caco-2

GI Tract Epith.

59%

70%

SE

V4XC-1032

V4SC-1096

Caco-2/TC7

GI Tract Epith.

56–71%

60–75%

SE/SF/SGV4XC-9064

V4SC-9096

Cal-85-1

Mammary Epith.

SF

V4XC-2032

V4SC-2096

CAL51

Mammary Epith.

90%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

Calu-3

Respiratory Tract Epith.

40%

VCA-1003

SE

V4XC-1032

V4SC-1096

Calu-6

Respiratory Tract Epith.

73%

50–87%

SE/SF/SGV4XC-9064

V4SC-9096

CAMA 1

Mammary Epith.

CAP (CEVEC‘s Amniocyte Production)

Embryonic/
Extraembryonic Epith.

90%

80%

Capan-1

Pancreas Epith.

29%

78%

Capan2

Pancreas

50–70%

50–70%*

Cat.No.

VCA-1002*

Efficiency

89-97%

Viability*

58-68%

55%
65–70%

70–75%C* indicates Lonza validated data

*

*

*

VCA-1003

VCA-1003

VCA-1002

75-80%

92%82%

70-73%

55-70%

70-80%***

VCA-1002
VCO-1001N

70–80%
70-81%

VCA-1005
VCO-1001N*

85%

54-90%*SF

V4XC-2032

V4SC-2096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Nucleofector™ 2b/ lls

4D-Nucleofector™ and 96-well Shuttle™

Cell Name (short)

Cell Type

Efficiency

Viability*

Cat.No.

CCRF-CEM

T Cell

68%

79%

*

CCRF-CEM C7

T Cell60%

95–99%

CEM-C7A

T Cell50–80%

CEM.C1

T Cell25%

CFBE

Respiratory Tract Epith.

31%

CH1

B cellCH12

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

70%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

99%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

85%

80%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

B cell73–75%

62–99%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

CH27

B cell30–40%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

CHM 2100

Blood/Bone Marrow SC

41%

80–96%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

CHO [suspension]

Ovary Epith.

92%

82%

SE/SF/SGV4XC-9064

V4SC-9096

CHO-DG44 (DHFR-)

Ovary Epith.

93%

95%

SG

V4XC-3032

V4SC-3096

CHO-K1

Ovary Epith.

84–94%

53–96%

CHO-S [suspension] (LifeTechnologies)

Ovary Epith.

90–98%

67–72%

Colo201

GI Tract Epith.

57%

78–96%

Colo205

GI Tract Epith.

30–68%

70–80%

Colo357

Pancreas Epith.

40–56%

COS-1

Fibroblast

49%

64%

COS-7

Fibroblast

99%

94%

CRFK

Kidney Epith.

80%

65–80%

CV1

Fibroblast

70%

90%

D1 ORL UVA

Stromal cell

61%

97%

D1F4

T Cell

45%

80%

D283

Neuroblast

40%

D54

Glial Cells

75%

Dante-BL

Leukocyte (unspec.)

20%

Daudi

Leukocyte (unspec.)

51%

DEV

Leukocyte (unspec.)

DLD-1

GI Tract Epith.

DOHH-2*

Efficiency

Viability*

VCA-1003
VCA-1003

90-95%

80-95%*

VCA-1002

76-86%

68-97%*SF

V4XC-2032

V4SC-2096*

VCA-1003

86%

55–57%*SG

V4XC-3032

V4SC-3096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096*

VCA-1001

SE

V4XC-1032

V4SC-1096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

56%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

60–90%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

70%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

60%

70–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

80–90%

90%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

B cell35%

49–86%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

DOV13

Ovary Epith.

34%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

DT40

B cell60–80%

42–84%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

DU 145

Prostate Epith.

47%

89%

SE

V4XC-1032

V4SC-1096

EAhy926

Umbilical Vein Endo.

59%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

eCAS

Monocyte

23–28%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

91–99%

80–96%*

D**

VCA-1005

89-100%70-92%*

E* indicates Lonza validated data80%

Nucleofector™ 2b/ lls

4D-Nucleofector™ and 96-well Shuttle™

Cell Name (short)

Cell Type

Efficiency

Viability*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

ECC-1

Uterine/Vaginal Epith.

70–80%

95%

EcR293Kidney Epith.

80%

60%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

ECV304

Bladder Epith.

50%

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

EL4

T Cell

65%

76%

EMC

Mesothelium

80–90%

95%

VCA-1005

SF

V4XC-2032

V4SC-2096

SE/SF/SGV4XC-9064

EpH4

Mammary Epith.

27–35%

50%

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

ESS-1 (DSMZ)

Endometrial cell70%

V4SC-9096

80%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

F36P

Erythroblast

F9

Embryonic/
Extraembryonic Epith.

80%

75–90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

63%

75–95%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

FaO

Liver Epith.

63%

93%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

FDC-P1

Leukocyte (unspec.)

82%

84%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

FDCP-Mix (DSMZ)

Leukocyte (unspec.)

93%

15–91%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

FL5.12A

B cell70%

90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

FM3A (RIKEN)

Mammary Epith.

30–50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

G-361

Skin/Hair Epith.

66%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

GaMG

Glial Cells

83%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

GD25

Fibroblast

40%

90%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

GH3

Pituitary Gland Epith.

77%

84%

SE

V4XC-1032

V4SC-1096

GIST882

Stromal cell

50%

85%

SE/SF/SGV4XC-9064

V4SC-9096

GM00131 (Coriell)

B cellSF

V4XC-2032

V4SC-2096

GM05849 (Coriell)

Fibroblast

30–40%

80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

GM09582 (Coriell)

B cell30%

50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Granta519

B cell43%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

GT1-7

Neurons (Brain)

70–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

H4

Glial Cells

80%

H4IIE

Liver Epith.

50–65%

H69

Cholangiocyte

53%

H9

T CellH9c2(2-1)*

Cat.No.

VCA-1005

Efficiency

90%

Viability

86-92%

*

*

F

*

G
83%

*

VCA-1005

60–80%

60–70%*

VCA-1003
VCO-1001N

45–56%

50–64%H
SG

V4XC-3032

V4SC-3096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

93%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

51–57%

48–83%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Myoblast

86%

90%

SF

V4XC-2032

V4SC-2096

HaCaT

Skin/Hair Epith.

43%

HC11

Mammary Epith.

30–80%

80–90%HCA7

GI Tract Epith.

72–84%

HCC1937

Mammary Epith.

30%* indicates Lonza validated data

80–90%

VCA-1003

72–78%*

VCA-1005

80-90%

54-72%**

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

83–91%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

70–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

Viability

HCC1954

Mammary Epith.

50%

70–80%

HCT 116

GI Tract Epith.

78%

76%

HCT15

GI Tract Epith.

78–80%

80–90%

HDLM-2

T Cell60–70%

HDQ-P1

Mammary Epith.

HEL 92.1.7

Erythroblast

94%

HeLa

Uterine/Vaginal Epith.

70%

HeLa S3

Uterine/Vaginal Epith.

67%

Hep G2

Liver Epith.

41–64%

Hep1B

Liver Epith.

50–56%HEPA 1-6 (DSMZ)

Liver Epith.

22–60%

Hepatocyte immortalized, mouse

Liver Epith.

20–70%

HFF, immort.

Fibroblast

HFFF2

4D-Nucleofector™ and 96-well Shuttle™
**

Cat.No.

Efficiency

VCA-1005

55–57%

VCA-1003

70–80%

Viability*

65–75%*

VCA-1003
VCA-1002

39–66%

VCO-1001N

48%

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

SE

V4XC-1032

V4SC-1096

SE

V4XC-1032

V4SC-1096

SE/SF/SGV4XC-9064

V4SC-9096

SE/SF/SGV4XC-9064

V4SC-9096

SE

V4XC-1032

V4SC-1096

VCA-1003

80%60%SE/SF/SGV4XC-9064

V4SC-9096*

VCA-1001

60-85%

80-89%*SE

V4XC-1032

V4SC-1096

95%*

VCA-1005

45–85%

58–95%*SE

V4XC-1032

V4SC-1096

86–94%*

VCA-1003

72–95%92%*

SF

V4XC-2032

V4SC-2096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

45–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

55–70%

50–70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Fibroblast

70%

70%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

HIB1B

Adipocyte

60–71%

90–95%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

HK-2

Kidney Epith.

83–86%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

HL-1

Cardiac Muscle

70%

50–70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

HL-60

Leukocyte (unspec.)90%50–65%

HMC-1

Granulocyte

60–72%

HMEC-1

Microvascular Endo.

HMLE

Mammary Epith.

HMy2.CIR

B cellHN5Skin/Hair Epith.

60%

HPB-ALL

T Cell75%

Hs 181.Tes

Testes Epith.

69%

60%

HT-1080

Fibroblast

74%

76%

*

VCA-1002

98%

71-81%*HT-29

GI Tract Epith.

16–51%

57–94%*

VCA-1001

51-67%

60%*

HT29-D4

GI Tract Epith.

70%

HTC

Liver Epith.

75%

HU609

Bladder Epith.

39%

HuH7

Liver Epith.

60–90%

HuT 102

T Cell73%

HuT 78

T Cell53%

64%

HUV-EC-C

Umbilical Vein Endo.

75%

77%

IEC-6

GI Tract Epith.

62–90%

50–90%

IEC18

GI Tract Epith.

60%

IGROV1

Ovary Epith.

73%*

VCA-1003

45–58%

49-61%*SF

V4XC-2032

V4SC-2096

76–99%

VCA-1003

78-81%

73-78%*SF

V4XC-2032

V4SC-2096

69–74%

78–83%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

70–80%

80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

55%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

85%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

SE/SF/SGV4XC-9064

V4SC-9096

SF

V4XC-2032

V4SC-2096

SF

V4XC-2032

V4SC-2096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

95%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096*

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

70%

I* indicates Lonza validated data

85–94%

Nucleofector™ 2b/ lls
Viability

4D-Nucleofector™ and 96-well Shuttle™

Cell Name (short)

Cell Type

Efficiency*

Cat.No.

Efficiency

Viability

IHH

Liver Epith.

68%

IM9

B cell58–62%

87%

IMR-32

Neuroblast

80%

62%

*

VCA-1005

74-86%

45-63%

IMR-90Fibroblast

51%

70%

*

VCA-1001

65%

70%

INS-1

Pancreas

70–90%

75–85%

INS-1E

Pancreas

75–100%

INS1 832/13

Pancreas

65–70%

IOSE29Ovary Epith.

IOSE80*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096*

SF

V4XC-2032

V4SC-2096*

SE

V4XC-1032

V4SC-1096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

60%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

Ovary Epith.

60%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

J-774

Macrophage30%

VCA-1003

SF

V4XC-2032

V4SC-2096

J-Lat 6.2

T Cell95%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

J558L

B cell50–63%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

J774A.1

Macrophage75%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

JB6-1

T Cell42%61–70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

JB6-2

T Cell20%

80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

JeKo-1

B cell74%

48%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

JurkatT Cell

88%

90%

SE

V4XC-1032

V4SC-1096

Jurkat-modified

T Cell70%

75–83%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

JVM

B cell63%

50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

JVM-2 (DSMZ)

B cell32%

72%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

K-562 (DSMZ)

B cell80–90%88%

SF

V4XC-2032

V4SC-2096

Karpas 299

T Cell56–57%

50–77%

SE/SF/SGV4XC-9064

V4SC-9096

KE-37 (DSMZ)T CellSF

V4XC-2032

V4SC-2096

Kelly

Neuroblast60%

35–50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

KG-1

Myeloid (unspec.)

70%

84%

*

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

KG-1a

Myeloid (unspec.)

86%

79%

*

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

KHYG1

Natural Killer (NK)

56%

73%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

KIT225

T Cell28%

71–80%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

KM-H2

Leukocyte (unspec.)

60–70%

70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

KS

Lymphatic Endo.

52%

70–95%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

KTA2

Thyroid Epith.

30–35%

75–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Ku812

Granulocyte

SE/SF/SGV4XC-9064

V4SC-9096

80–85%

J

37–88%*

VCA-100330%

76–92%

60–80%*

K* indicates Lonza validated data*

VCA-1003

90–92%

68–95%

VCA-1003
VCO-1001N

23-69%

30–75%*

Nucleofector™ 2b/ lls
Cell Name (short)

4D-Nucleofector™ and 96-well Shuttle™

Cell Type

Efficiency

Viability*

Cat.No.

L-428 (DSMZ)

Leukocyte (unspec.)

78%

73%

*

L1.2

B cell15–47%

55–90%

L1210

Leukocyte (unspec.)

70%

L1236

Leukocyte (unspec.)

L3.6SL

Pancreas Epith.

L5178YB cellL540

Efficiency

Viability*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

60–70%

42%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

60%

70–90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Leukocyte (unspec.)

50%

60%

L6

Myoblast

59%

92%

L87/4

Stromal cell

30%

LA-N-5

Neuroblast

LAMA-84 (DSMZ)LAZ 221

L

VCO-1001NSG

V4XC-3032

V4SC-3096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

61–66%

71–96%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Granulocyte

80%

85%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

B cell38%

80–97%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

LbetaT2

Pituitary gland80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

LCL

B cell75%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

LLC-MK2

Kidney Epith.

56%

60%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

LLC-PK1

Kidney Epith.

54–88%

17–81%

VCA-1005

SF

V4XC-2032

V4SC-2096

LLC-PK10

Kidney Epith.

60–70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

LN229

Glial Cells

95%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

LNC

B cell

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

LNCaP

Prostate Epith.

82%

70–80%SF

V4XC-2032

V4SC-2096

LoVo

GI Tract Epith.

65–80%

50–90%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

LP1 (DSMZ)

B cell24–54%

45–87%LS180

GI Tract Epith.

LX-2

Fibroblast

70–90%

LY2

Skin/Hair Epith.

75–85%

M-07e

Megakaryocyte

M28

Mesothelium

MA 104

Kidney Epith.

52%

MC-38

GI Tract Epith.

70–80%

MC/9

Granulocyte

68%

64%

VCA-1003

MC3

T Cell83%

68–82%

MC3T3

Bone

60–70%

MC3T3-E1 (RIKEN)

Bone

20%

MC57G

Fibroblast

65–70%

McA-RH7777

Liver Epith.

*81–86%*

VCA-1001

90–92%

90-94%

70%

89–97%

83-90%

45%*

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

80–90%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

50–77%

34–62%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

70–85%

99%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

SE/SF/SGV4XC-9064

V4SC-9096

SF

V4XC-2032

V4SC-2096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

M* indicates Lonza validated data

VCA-1003

95%

55–63%

65–70%

Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

MCF10

Mammary Epith.

40–70%

MCF10A

Mammary Epith.

65–92%

65–92%

SE/SF/SGV4XC-9064

V4SC-9096

SE

V4XC-1032

MCF7

Mammary Epith.

77%

60%

V4SC-1096

SE

V4XC-1032

V4SC-1096

MCF7 tet

Mammary Epith.

66%

74–88%

MCT

Unknown

38–40%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

MDA-MB-231

Mammary Epith.

79%

V4SC-9096

SE

V4XC-1032

MDA-MB-361

Mammary Epith.

45%

V4SC-1096

SE/SF/SGV4XC-9064

MDA-MB-415

Mammary Epith.

V4SC-9096

SF

V4XC-2032

V4SC-2096

MDA-MB-453

Mammary Epith.

54%

90%

*

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

MDA-MB-468

Mammary Epith.

60%

81%

MDBK

Kidney Epith.

59%

96%

*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096*

VCA-1001

SE/SF/SGV4XC-9064

MDCK

Kidney Epith.

73%

V4SC-9096

83%*

VCA-1005

72-90%

51-90%SE

V4XC-1032

MDCK II (ECACC)

Kidney Epith.

80%

V4SC-1096

88%*

VCA-1005

93%

69%

SF

V4XC-2032

MDCK-C7

Kidney Epith.

90–95%

V4SC-2096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

ME-1

Myeloid (unspec.)

20%

MedB1

B cell34%

65%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

MEG-01

Megakaryocyte

80%

66%

V4SC-9096

SF

V4XC-2032

MEL

Erythroblast

30%

V4SC-2096

VCA-1001

SE/SF/SGV4XC-9064

melan-aSkin/Hair Epith.

60%

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Meso17

Mesothelium90%

Met-1fvb2

Mammary Epith.

95%

90%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

90%VCA-1003

SE/SF/SGV4XC-9064

MEWO

Skin/Hair Epith.

60%

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

MFM223

Mammary Epith.

13–36%

80–90%

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

MG-63

Bone

62%

90%

V4SC-9096

SE

V4XC-1032

V4SC-1096

MHP36

Neurons (Brain)

70–80%MiaPaCa

Pancreas Epith.

80%

57–90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

mIMCD3Kidney Epith.

68–70%

86–91%

VCA-1001

V4SC-9096

SF

V4XC-2032

MIN6

Pancreas60–75%

40–80%

V4SC-2096

VCA-1002

SE/SF/SGV4XC-9064

Mino

B cell30–40%

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

MKN-1

GI Tract Epith.

75%

V4SC-9096

65–70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

mlEND

Lymphatic Endo.

MLO-Y4Bone

35–40%

75–90%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

50%

55%

VCA-1003

SE/SF/SGV4XC-9064

MLP29

Liver Epith.

68%

V4SC-9096

VCA-1005

SE/SF/SGV4XC-9064

MM.1S

B cell50%

V4SC-9096

50–63%

VCA-1003

SE/SF/SGV4XC-9064

MN9D

Neurons (Brain)

V4SC-9096

80%

80%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

MOLM-14

Monocyte

MOLT-4

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

T Cell55%

61%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

Molt16

T Cell61%

50–68%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

MonoMac1 [MM1]

Monocyte

52–55%

54–92%

VCA-1001

SF

V4XC-2032

V4SC-2096* indicates Lonza validated data

Viability

4D-Nucleofector™ and 96-well Shuttle™
*

Cat.No.

Efficiency

Viability*

VCA-1003

77%

*

*

VCA-1005

50-90%

VCA-1003

72-78%

VCA-1003

59%

73–89%**

VCA-1002
VCO-1001N***

VCA-1004

VCA-1004

85%

67-74%

70-73%

90%40%

61-79%

60-65%

70–80%

63%

*

*

*

Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

Viability

MonoMac6 [MM6]

Monocyte

50–70%

49–95%

Mouse L cell

Fibroblast

20–50%

95%

MPC-11

B cell22%

Mpf

Neurons (Brain)

99%

mpkCCD(c14)

4D-Nucleofector™ and 96-well Shuttle™
*

Cat.No.

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

95%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

99%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

SF

V4XC-2032

V4SC-2096

SE/SF/SGV4XC-9064

V4SC-9096

SE

V4XC-1032

V4SC-1096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

60–95%

VCA-1005
VCA-1003

Efficiency

70–80%

Viability

*

98%

MPRO

Glial Cells

37%

MRC-5

Fibroblast

92%

MT4

T Cell60%

MTC

Mammary Epith.

42%

50–60%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

MTLn3

Mammary Epith.

30–43%

50–60%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

Mutu1

B cell42–57%

24–80%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

MUTZ-2 (DSMZ)

Myeloid (unspec.)55%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

MUTZ3

Leukocyte (unspec.)

20%

90%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

MV-4-11

Leukocyte (unspec.)

29%

79%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

MzCHA-1

Cholangiocyte

30–35%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

N11

Glial Cells

90%

80%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

N114P2

B cell35%75–85%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

N1E115

Neuroblast

20%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

N9

Glial Cells

53–58%

63–74%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

NALM-6 (DSMZ)

B cell64%

87%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

Namalwa

B cell10–15%

90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

NB-4 (DSMZ)

Myeloid (unspec.)

71%

66%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

NBL-6

Fibroblast

57–64%

90%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NCEB-1

B cell30%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NCI-H1299 [H1299]

Respiratory Tract Epith.

99%

75%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

NCI-H1435

Respiratory Tract Epith.

36%

70%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

NCI-H2170

Respiratory Tract Epith.

50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

NCI-H226 [H226]

Respiratory Tract Epith.

50–60%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

70–80%

VCA-1001*

84-86%

67-73%*

N

NCI-H292 [H292]***

70–90%

70–95%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

90%VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

NCI-H295R [H295R]

Adrenal Epith.

98–99%

NCI-H358 [H-358; H358]

Respiratory Tract Epith.

82%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NCI-H460 [H460]

Respiratory Tract Epith.

56%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NCI-H69 [H69]

Respiratory Tract Epith.

16%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NCI-H929 [H929]

B cell18–28%

49–78%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NCM460GI Tract Epith.

52–59%

70–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

NCTC clone 929

Adipocyte

67%

91%

*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Neuro-2a [N2a]Neuroblast

76%

79%

*

VCA-1003

SF

V4XC-2032

V4SC-2096* indicates Lonza validated data

46–90%

81–97%*

Nucleofector™ 2b/ lls

4D-Nucleofector™ and 96-well Shuttle™

Cell Name (short)

Cell Type

Efficiency

Viability*

Cat.No.

NG108-15

Glial Cells

64%

82%

*

VCA-1003

NIH/3T3

Fibroblast

84%

87%

*

VCA-1001

NK-92

Natural Killer (NK)

26%

40%

*

NK3.3

Natural Killer (NK)

56%

NKL

Natural Killer (NK)

9–70%

NKL1

Natural Killer (NK)NRK

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

SE/SF/SGV4XC-9064

V4SC-9096

SG

V4XC-3032

V4SC-3096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

80%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

60–90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

47–62%

65%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

Kidney Epith.

44%

91%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NRK-49F

Fibroblast

43–54%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NRK52E

Kidney Epith.

90%

50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

NS0 (ECACC)

B cell83%

54%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

NS1

B cell53%

49–64%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

NSC34

Neuroblast

90%

50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

NTERA-2 cl.D1

Testes Epith.

90%

94%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

OCI-AML1a

Myeloid (unspec.)

90%

86–92%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

OCI-AML2

Myeloid (unspec.)

52%

65%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

OCI-AML3

Myeloid (unspec.)

50–60%

50–90%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

OCI-LY-10

B cell49%

70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

OCI-LY-3

B cell

61–63%

61–75%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

67%

67%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Ovary Epith.

70–80%

70–95%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

P19

Embryonic/
Extraembryonic Epith.

85%

80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

P3X63Ag8

B cell35%

78–90%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

P815

Granulocyte

62%

92%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

PAC2

Fish

40–50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Pam212

Skin/Hair Epith.

40%

60–70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

PANC-1

Pancreas Epith.

68%

75%

SE

V4XC-1032

V4SC-1096

Panc89Pancreas Epith.

25%

SE/SF/SGV4XC-9064

V4SC-9096

PC-12

Adrenal Cells

92%

81%

*

VCA-1003

83%

54-57%*SF

V4XC-2032

V4SC-2096

PC-3

Prostate Epith.

88%

59–66%*

VCA-1003

83%

79%

*

SF

V4XC-2032

V4SC-2096

PLB-985

Myeloid (unspec.)

60%

75%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

PMC42

Mammary Epith.

30–50%

35–66%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

PS1

Smooth muscle cell

29–49%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

PtK1

Kidney Epith.

86%

SE

V4XC-1032

V4SC-1096***

Efficiency

Viability*

90–95%

51–93%*O

OP-6
OVCAR3P* indicates Lonza validated data

*

*

*

VCA-1001

83-91%

51-61%*

VCA-1002

85–95%

VCA-1001

90%

80%

Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

Viability

R28

Eye Epith.

30%

70–95%

R9ab

Fibroblast

70%

75–90%RAEL

B cell15%

RAG2-/- R2BM3-7

Blood/Bone Marrow SC

Raji

4D-Nucleofector™ and 96-well Shuttle™
*

Cat.No.

Efficiency

Viability*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

87%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

67%

87%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

B cell84%

67–81%*

VCA-1003

65-69%

71%*

SG

V4XC-3032

V4SC-3096

Ramos

B cell

27%

72%

*

VCA-1003

40-51%

70-77%*SG

V4XC-3032

V4SC-3096

Rat2

Fibroblast

50%

95%

SE/SF/SGV4XC-9064

V4SC-9096

RAW 264.7

Macrophage

65%

74%

SF

V4XC-2032

V4SC-2096

RBL

Granulocyte

60%

70%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

RBL-1

Granulocyte

83%

67%

*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

RBL-2H3

Granulocyte

42%

93%

*

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

RCC26

Kidney Epith.

70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

REH

B cell

55–68%

50–70%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

Renal Cell Carcinoma

Kidney Epith.

82%

91%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

RF/6A

Eye Endo.

60%

76–91%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

RFL-6

Fibroblast

50–60%

50–75%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

Rh4

Myoblast

40%

60%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

Rin 1046

Pancreas

70–90%

87–95%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

RIN m5f

PancreasSF

V4XC-2032

V4SC-2096

RKO

GI Tract Epith.

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9065

V4SC-9097

R

RL-952

VCA-1001*

VCA-1003

VCO-1001N
70%

80%

47%

60%

52%

86%

59%

*

*

RMAS

Leukocyte (unspec.)

60%

94%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

RPMI8226

B cell37%

70–83%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

RS4-11

B cell56–59%

58–81%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

RT4

Bladder Epith.

17%

90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

RWPE-1

Prostate Epith.

40–43%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

S1A.TB.4.8.2

T Cell89%

66%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

S49

T Cell81%

68–95%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

SA1N

Fibroblast

75%

52%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

SAM-19

T Cell56%

74–75%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Saos-2

Bone

82%

79%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

SbCl2

Skin/Hair Epith.

50–60%

60–75%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Schneider‘s Drosophila Line 2

Insect77%

64–70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Schwannoma cell line

Glial Cells

50%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

SCI-ET27

Blood/Bone Marrow SC

58–60%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

S* indicates Lonza validated data

98%

*

*
*

Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

Viability

SCID.adh

T Cell40%

85%

SET-2 (DSMZ)

Leukocyte (unspec.)

Sf9

Insect82%

76–79%

SGHPL-4

Embryonic/
Extraembryonic Epith.

82%

78–82%SH-SY5Y

Neuroblast

63–82%

40%

SIRC

Fibroblast99%

94–97%

SK-BR-3

Mammary Epith.

50%

94%

SK-MEL 100

Skin/Hair Epith.

50%

SK-MEL 103

Skin/Hair Epith.

SK-MEL 147

Skin/Hair Epith.

SK-MEL 173

4D-Nucleofector™ and 96-well Shuttle™
*

Cat.No.

Efficiency

Viability*

SE/SF/SGV4XC-9064

V4SC-9096

VCO-1001N

80–90%

80–90%SF

V4XC-2032

V4SC-2096

VCA-1001

100%

48–64%SF

V4XC-2032

V4SC-2096

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003*

VCA-1003

SF

V4XC-2032

V4SC-2096

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

80%

VPD-1003

SE/SF/SGV4XC-9064

V4SC-9096

50%

70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

50–60%

70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

Skin/Hair Epith.

80%

70–80%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 187

Skin/Hair Epith.

20–30%

60%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 19

Skin/Hair Epith.

70–80%

50–60%

VPD-1003

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 192

Skin/Hair Epith.

30–40%

50%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 197

Skin/Hair Epith.

80%

95%

VPD-1003

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 23

Skin/Hair Epith.

40–60%

60–70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 29

Skin/Hair Epith.

30–40%

50%

VPD-1003

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 31

Skin/Hair Epith.

40%

80%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 85

Skin/Hair Epith.

80%

80%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL 94

Skin/Hair Epith.

80–90%

50–60%

VPD-1003

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL-28

Skin/Hair Epith.

35%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

SK-MEL-5

Skin/Hair Epith.

SK-N-MC

Neuroblast

60–80%

30–60%

SK-N-SH

Neuroblast

85%

73%

*

VCA-1003

SK-OV-3

Ovary Epith.

89%

53%

*

SKNAS

Neuroblast

41–57%

55–82%

SKW6.4

B cell20%

Sp2/0-Ag14

Hybridoma, mouse

37-71%

SP53

B cell30–40%

Stroco5

Neuroblast

57–65%SUIT-2

Pancreas Epith.

65%

SUM52PE

Mammary Epith.

80%

SUP-T1

T Cell

29–68%SVEC 4-10

Microvascular Endo.

69%

SW13

Adrenal Epith.

40%

SW1353

Cartilage

80%

90%

SW48

GI Tract Epith.

38–48%

80%

SW480

GI Tract Epith.

60%

86%

*

VCA-1003

81%

80%

*

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1003* indicates Lonza validated data*

Solution

VCO-1001N

50%

SE

V4XC-1032

V4SC-1096

VCA-1003

50-95%SF

V4XC-2032

V4SC-2096

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

80-90%

VCA-1001

SF

V4XC-2032

V4SC-2096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

65–83%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

95%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

74–98%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

91%

VPI-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096*

65-69%

80-90%*

Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

Viability

SW620

GI Tract Epith.

50–65%

50–70%SW837

GI Tract Epith.

80%

SW872

Adipocyte

40–50%

SZ95

Skin/Hair Epith.

T cell line, chicken

4D-Nucleofector™ and 96-well Shuttle™
*

Cat.No.

Efficiency

Viability*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

65–90%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

70%

40%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

T Cell20–30%

99%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

T-47D

Mammary Epith.

51%

94%

*

VCA-1003

SE

V4XC-1032

V4SC-1096

T/C-28 a2

Cartilage

90%

80%

*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

T/G HA-VSMC

Smooth muscle cell

58%

79%

*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

T0

Fish

40%

85%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

T1165

Leukocyte (unspec.)

31%

83%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

T2

Leukocyte (unspec.)

60%

68%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

T24

Bladder Epith.

64%

92–93%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

T84

GI Tract Epith.

53%

83%

SF

V4XC-2032

V4SC-2096

TA3

Mammary Epith.

96%

80–94%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

TF-1

Erythroblast

38%

82%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

TG40

T Cell43–59%

65%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

THP-1

Monocyte

47–68%

40–58%

TK6

Leukocyte (unspec.)

19–42%

TOM-1 (DSMZ)

B cell44%

Tot2

Myeloid (unspec.)

TS/A
TT

T

*
*
*
*

VCA-1002

VCA-1003

80%

88%

58–65%*

50-70%

52–81%*SG

V4XC-3032

V4SC-3096

VCA-1003*

SE/SF/SGV4XC-9064

V4SC-9096

63%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

26–30%

60–65%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Mammary Epith.

35–45%

63–70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Thyroid Epith.

45–60%

40–60%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

U-2 OS

Bone

98%

88%

*

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

U-87 MG

Glial Cells

43%

91%

*

VCA-100275%

40-50%*SE

V4XC-1032

V4SC-1096

U-937

T Cell

67%

85%

*

VCA-1004

32–39%

62–89%*SG

V4XC-3032

V4SC-3096

U138MG

Glial Cells

70%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

U251

Glial Cells

96%

93–95%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

U251MG

Glial Cells

91%

70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

U266B1

B cell86%

91%

VCA-1004

SE/SF/SGV4XC-9064

V4SC-9096

U373

Glial Cells

71%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

U373MG

Glial Cells

70%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

U87

Glial Cells

70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

UACC903

Skin/Hair Epith.

90%

55–75%

VCA-1001

SF

V4XC-2032

V4SC-2096

UMR 106-01

Bone

80–90%

50–90%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

UMSCC-14A

Skin/Hair Epith.

20–38%

54–70%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

U* indicates Lonza validated data

99%

*

80%

Nucleofector™ 2b/ lls
Cell Name (short)

Cell Type

Efficiency

UT7

Myeloid (unspec.)

91–96%

UT7 GM-CSF dependent

Myeloid (unspec.)

70%

UT7-Epo

Myeloid (unspec.)

29–80%

UT7-EpoS1

Myeloid (unspec.)

UT7-TPO

Myeloid (unspec.)

V5

Skin/Hair Epith.

63–76%

V79

Fibroblast

80%

VAL

B cellVero

Viability

4D-Nucleofector™ and 96-well Shuttle™
*

Solution

Cat.No.
Cat.No. 96-well
4D-Nucleofector˝ Shuttle™

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

25–50%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

70%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

47–59%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

79%

75%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Fibroblast

79%

97%

*

VCA-1003

SF

V4XC-2032

V4SC-2096

WEHI-231

B cell

77%

62%

*

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

WEHI-279

B cell72%

56%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

WERI-Rb-1

Neurons (Ganglia)

70–80%

70–80%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

WI-38

Fibroblast

75%

91%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

WIL2-S

B cell

16–23%

49–71%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

WM-266-4

Skin/Hair Epith.

45–55%

80–90%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

WM35

Skin/Hair Epith.

30%

60–75%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

WRO

Thyroid Epith.

80%

50–60%

VCA-1005

SE/SF/SGV4XC-9064

V4SC-9096

XG6

B cell90%

80–96%

VCA-1002

SE/SF/SGV4XC-9064

V4SC-9096

YT

Natural Killer (NK)50%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

YTS

Natural Killer (NK)53%

VCA-1001

SE/SF/SGV4XC-9064

V4SC-9096

Zebrafish cell line

Fish

30%

VCA-1003

SE/SF/SGV4XC-9064

V4SC-9096

Z-138

B cellSF

V4XC-2032

V4SC-2096

ZF4

Fish

SE/SF/SGV4XC–9064

V4SC–9096

84%

Cat.No.

Efficiency

Viability

*

V

92%

80-95%

*

W

*

X–Z

* indicates Lonza validated data

50–60%

70-75%
70%

VCA–1003

83-86%

www.lonza.com/researchContact Information
North America
Customer Service: +1 800 638 8174 (toll free)order.us@lonza.com
Scientific Support: +1 800 521 0390 (toll free)scientific.support@lonza.com

EuropeCustomer Service: +32 87 321 611
order.europe@lonza.com
Scientific Support: +32 87 321 611
scientific.support.eu@lonza.com

International
Contact your local Lonza distributor
Customer Service: +1 301 898 7025
Fax:					+1 301 845 8291
scientific.support@lonza.com

International Offices
Australia			Belgium			Brazil				France				Germany			
India				Japan				Luxemburg		
Singapore		
The Netherlands
United Kingdom+ 61 3 9550 0883
+ 32 87 321 611+ 55 11 2069 8800
0800 91 19 81 (toll free)
0800 182 52 87 (toll free)+91 40 4342 4000
+ 81 3 6264 0660
+32 87 321 611+ 65 6521 4379
0800 022 4525 (toll free)
0808 234 97 88 (toll free)

Lonza Cologne GmbH50829 Cologne, Germany
For Research use only. Not for use in diagnostic
procedures.
The Nucleofector™ Technology is covered by patent
and/or patent pending rights owned by Lonza Cologne
GmbH.
FreeStyle™ is a trademark of Life Technologies.
All trademarks belong to Lonza or its affiliates or totheir respective third party owners. The information
contained herein is believed to be correct andcorresponds to the latest state of scientific andtechnical knowledge. However, no warranty is made,either expressed or implied, regarding its accuracy
or the results to be obtained from the use of suchinformation and no warranty is expressed or implied
concerning the use of these products. The buyer
assumes all risks of use and/or handling. Any user
must make his own determination and satisfy himselfthat the products supplied by Lonza Group Ltd or its
affiliates and the information and recommendations
given by Lonza Group Ltd or its affiliates are (i) suitablefor intended process or purpose, (ii) in compliance withenvironmental, health and safety regulations, and (iii)
will not infringe any third party’s intellectual property
rights.
©2015 Lonza. All rights reserved.
CD-LI001 11/15